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Objectives. This study sought to report the long-term result (up
to 8 years) of percutaneous transluminal balloon angioplasty
(PTBA) for Budd-Chiari syndrome (BCS) caused by membranous
obstruction of the inferior vena cava (MOVC).
Background. We previously reported on this nonoperative form
of therapy in a smaller series of patients and found the short-term
results to be excellent.
Methods. We studied the long-term results of PTBA in the
treatment of BCS caused by MOVC in 42 patients who underwent
PTBA with the Inoue balloon catheter between June 1988 and
February 1996. There were 28 men and 14 women with a mean age
of 35.6 years (range 16 to 56). MOVC was incomplete in 27
patients and complete in 15. PTBA was successful in 38 patients
(91%). The longest follow-up period was 8 years.
Results. All 38 patients who successfully underwent PTBA
showed marked symptomatic improvement. Immediately after
PTBA, the diameter of the inferior vena cava at the MOVC
increased from 1.7  2 to 19.9  3.5 mm (p < 0.0001), the caval
pressure below the MOVC decreased from 23.6  8.5 to 12.0 
6.5 mm Hg (p < 0.0001), and the enlarged liver size decreased
from 6.5 1.5 to 2.0 1.5 cm below the right costal margin at the
midclavicular line (p < 0.0001). Over a follow-up period of up to
8 years (7 to 8 years in 4 patients, 5 to 7 years in 12, 3 to 5 years
in 11, 2 to 3 years in 6 and <2 years in 9), MOVC returned in only
1 patient. This patient, our ﬁrst, required a second PTBA 3 years
later and a third 4.25 years after the second PTBA, in combination
with stent placement for recurrence of stenosis.
Conclusions. PTBA with the Inoue balloon catheter is an
effective, safe and long-lasting alternative to surgical treatment of
patients with BCS due to MOVC.
(J Am Coll Cardiol 1996;28:1720–4)
1996 by the American College of Cardiology
In the past the Budd-Chiari syndrome (BCS) was always
treated surgically (1,2). The introduction of percutaneous
transluminal balloon angioplasty (PTBA) offers a new thera-
peutic option (3). We (3,4) previously reported our experience
with the use of the Inoue balloon catheter in treating BCS
caused by membranous obstruction of the inferior vena cava
(MOVC). In this report we address the long-term result (up to
8 years) of this form of treatment in 42 patients.
Methods
Patients. From June 1988 to February 1996, 42 patients
with MOVC underwent PTBA with the Inoue balloon cathe-
ter. There were 28 men and 14 women, ranging in ages from 16
to 56 years (mean, 35.6). The duration of their symptoms
ranged from 3 months to 12 years. Fifteen patients had
complete and 27 had incomplete MOVC.
One patient had had a previous surgical ﬁnger dilation
through a right atrial approach 6 months before PTBA.
Another had undergone surgical sympathectomy 12 years
before PTBA and had clinical recurrence of symptoms during
the 5 years preceding PTBA.
Procedure. The details of PTBA of MOVC with the Inoue
balloon catheter have been reported previously (3). Only a
brief description of some key points of the technique will be
presented here. For incomplete MOVC, a 0.025-in. (0.064-cm)
special guide wire was inserted through the percutaneously
inserted inferior vena cava catheter up to the right atrium, and
the caval catheter was then removed over the special guide
wire, which was left in situ in the right atrium. For complete
MOVC, an 8F Mullins introducer set was advanced over a
0.032-in. (0.081-cm) guide wire into the inferior vena cava up
to the level of obstruction. The guide wire was then exchanged
for a straight transseptal needle; the latter was pushed carefully
through the center of the MOVC under biplane ﬂuoroscopy
and pressure monitoring until the tip penetrated the MOVC
and was advanced to above the caval entrance into the right
atrium. The Mullins introducer set was then advanced over the
transseptal needle into the right atrium. Finally the straight
transseptal needle was exchanged for the special 0.025-in.
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guide wire and the Mullins introducer set removed. For the
rest of the procedure the readers are referred to our earlier
report (3).
In addition to intravenous administration of heparin,
4,000 U, during the procedure, all patients received continuous
heparin infusions, 6,000 U/day, for 1 week and oral aspirin,
100 mg/day, for 3 months after PTBA.
Follow-up studies. All patients initially had a detailed
history and physical examination as well as ultrasound studies,
catheterization with pressure measurement and angiographic
studies both before and after PTBA. Follow-up studies were
carried out at regular intervals by questionnaires in all patients
and by repeat clinical, esophagographic, two-dimensional ul-
trasonographic and angiographic examinations in most of our
patients whenever feasible. The duration of follow-up was 7 to
8 years in 4 patients, 5 to 7 years in 12, 3 to 5 years in 11, 2 to
3 years in 6 and 2 years in 9.
Statistical analysis. All data are expressed as mean
value SD. Comparisons were made by Student t test. Results
were considered statistically signiﬁcant if p  0.05.
Results
Procedural success rate. PTBA with the Inoue balloon
catheter was successful in 38 (91%) of 42 patients. The four
failures were due to massive pulmonary embolism resulting in
instantaneous death immediately after PTBA in one patient
with unrecognized thrombosis of the inferior vena cava and
were due to complete MOVC secondary to excessive thickness
(5 to 8 mm) of the obstructive membrane in three patients who
were successfully treated surgically by cavoatrial bypass graft-
ing.
Hemodynamic ﬁndings. All patients who underwent suc-
cessful PTBA showed signiﬁcant hemodynamic improvement.
The inferior vena cava pressure below the MOVC decreased
from 23.6  8.5 to 12.0  6.5 mm Hg (p  0.0001). In one
patient whose right atrial pressure was also measured, the
pressure in the right atrium above the MOVC and in the
inferior vena cava below the MOVC was 1 and 20 mm Hg,
respectively, before PTBA and 1 and 7 mm Hg, respectively,
after PTBA. Right atrial pressure was not measured in the
other patients.
Angiographic ﬁndings. The thickness of the MOVC mea-
sured 1 to 5 mm. The diameter of the inferior vena cava at the
site of the MOVC increased from 1.7  2 to 19.9  3.5 mm
(p  0.0001). The infra-MOVC diameter of the inferior vena
cava decreased from 40.0  12.2 to 22.4  8.4 mm after PTBA
(p  0.0001). The venous collateral vessels that existed abun-
dantly before PTBA disappeared after PTBA.
Follow-up evaluation. Clinical improvement was dramatic
in all of the patients. Abdominal pain, nausea, vomiting,
dyspnea on exertion and leg edema either disappeared or
diminished signiﬁcantly within 2 to 7 days after PTBA. The
enlarged liver decreased markedly from 6.5 1.5 cm below the
right costal margin at the midclavicular line to 2.0  1.5 cm
after PTBA (p  0.0001). In patients with ascites, prompt
diuresis occurred within 12 h after PTBA. Ultrasonography
showed complete resorption or marked diminution of ascites
within 3 weeks in most cases. Within 3 to 6 months, 28 (74%)
of 38 patients returned to normal physical activities, which
were very strenuous in most cases.
All 14 women in the study had either dysmenorrhea or
amenorrhea before PTBA; 6, although married for many years,
either were infertile or had repeated miscarriages before
PTBA. After PTBA, two women became pregnant within 1
year and each gave birth to a healthy full-term baby.
All but 1 of the 38 patients showed continued improvement
during a follow-up period of up to 8 years, as assessed both
subjectively and objectively by esophagography, ultrasonogra-
phy and angiography (Fig. 1). One patient, a 21-year old
woman, the ﬁrst patient in our series, remained asymptomatic
for 31 months, then showed recurrence of symptoms due to
restenosis (Fig. 2). After repeat PTBA she remained well for
another 4.25 years, when restenosis again developed and a
third PTBA was performed in combination with stent place-
ment (Gianturco-Rosch Z stent, 25 mm in diameter, 5 cm in
length) (Fig. 2). She remained well thereafter.
Discussion
Deﬁnition of BCS. BCS, a relatively uncommon but devas-
tating disorder, comprises a heterogeneous group of patho-
logic entities characterized by hepatic venous outﬂow obstruc-
tion and its attendant manifestations (5). The diversity of the
causes and clinical presentations of BCS is reﬂected both in
the variety of approaches to establish the diagnosis and in the
several medical and surgical therapies available.
BCS may be classiﬁed as primary or secondary depending
on its pathologic features. The primary type refers to congen-
ital obstruction of the hepatic veins or the hepatic portion of
the inferior vena cava. The secondary type, most common in
Western countries, refers to obstruction of the same anatomic
structures by a tumor or, more commonly, thrombus or
thrombi in patients with some systemic diseases, usually my-
eloproliferative disorders (6). Primary BCS is well known as
MOVC, which is most common in Oriental countries and
South Africa (3).
MOVC. MOVC is the most common cause of BCS world-
wide (7). It accounts for 33% of the total number of cases
reported in the world literature (8). MOVC is usually not
difﬁcult to diagnose, especially in countries where it is rela-
tively common, such as Japan, China, South Africa and India.
Clinical diagnosis is usually established on the basis of a
constellation of typical symptoms and signs of portal hyperten-
sion and inferior vena cava obstruction. A two-dimensional
Abbreviations and Acronymns
BCS  Budd-Chiari syndrome
MOVC  membranous obstruction of the inferior vena cava
PTBA  percutaneous transluminal balloon angioplasty
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ultrasonogram shows dilation of the inferior vena cava below
the suprahepatic caval web and dilation of the hepatic veins
(3). The latter ﬁnding is an important diagnostic feature
differentiating MOVC from hepatic cirrhosis, in which hepatic
veins are small, narrow and tortuous. Color and pulsed Dopp-
ler ultrasonograms of portal and hepatic veins show either
absence or reversal of ﬂow in the portal vein (3). Magnetic
resonance imaging is also useful and has the added advantages
of obtaining coronal and sagittal images, thus facilitating
detection of the inferior vena cava web and evaluating the
vessels without the need for contrast material (3). Further-
more, magnetic resonance imaging can also be used to distin-
guish slowly ﬂowing blood from intraluminal thrombus by
examining ﬁrst- and second-echo images; slow ﬂow usually
causes an increase in relative signal density on a second-echo
image, whereas thrombus shows either a lesser increase or a
decrease in relative signal intensity (“paradoxic enhance-
ment”) (3).
Differentiation between membranous obstruction and
thrombosis of inferior vena cava. Thrombus formation is not
an uncommon complication of MOVC, occurring in 28.6% (6
of 21) of patients (3). It is essential to exclude thrombosis of
the inferior vena cava before performing PTBA. The only
death in our series was in a patient with unrecognized throm-
bosis below the web in the inferior vena cava who died from
massive pulmonary embolism immediately after the procedure
(3). In addition to magnetic resonance imaging, inferior vena
cavography may offer some clue to the existence of a thrombus
because of differing shades of contrast density at the site of the
obstruction in the inferior vena cava (3). Thrombotic occlusion
of the inferior vena cava is an absolute contraindication to
PTBA.
PTBA versus operation. Although hepatic venous outﬂow
obstruction may be circumvented by different forms of opera-
tive decompression or shunting procedures (2,9) and liver
transplantation (1), surgical treatment of MOVC is far from
ideal. First, placing a synthetic graft in the venous system to
bypass the inferior vena cava obstruction is a difﬁcult proce-
dure (10). Second, the graft is also prone to occlusion despite
long-term anticoagulant therapy, possibly because the liver
may fall back on the graft and obstruct the ﬂow (10). Third,
synthetic grafts in patients with hepatic venous outﬂow ob-
struction (who may have an underlying clotting tendency) are
predisposed to a high rate of occlusion (10). Last, but not the
least, an 8-year patient survival rate of 100% in our series
compares very favorably with a cumulative 5-year survival rate
of 59% in the Johns Hopkins series of BCS as reported by
Klein et al (2).
Advantages of the Inoue balloon catheter. Because of our
extensive experience with the Inoue balloon catheter in percu-
taneous balloon mitral valvuloplasty (11), we chose this cath-
eter for management of MOVC. A single Inoue balloon is
large enough for the inferior vena cava. The diameter of the
inferior vena cava is usually 20 to 22 mm in adults. Using single
Inoue balloon catheter with a balloon inﬂation diameter of
21.6 1.9 mm (range 18 to 24) and a total number of 2.6 0.7
inﬂations (range 1 to 4), we obtained very satisfactory imme-
diate and long-term results. A balloon/inferior vena cava
diameter ratio of 1:1 to 1.1:1 seems to be optimal for MOVC
dilation. The Inoue balloon catheter is ideally suited for
dilating the MOVC, because the waist of the pillow-shaped
balloon tends to “lock” in the obstructing membrane once the
inﬂated distal portion of the balloon is pulled against the
MOVC and as the proximal portion of the balloon is being
Figure 1. Inferior vena cavograms from a 43-year old man with
MOVC treated by PTBA with a 6-year follow-up study. A, Before
PTBA showing severe MOVC (arrowhead) before the inferior vena
cava enters the right atrium, which was barely opaciﬁed. B, After
PTBA, showing disappearance of the MOVC (arrowhead) and prompt
dense opaciﬁcation of the right atrium. C, At follow-up 6 years later,
showing persistence of a widely patent inferior vena cava.
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Figure 2. Inferior vena cavograms from the ﬁrst patient in the series, a 21-year old woman
with MOVC treated by PTBA and recurrences. Before PTBA, the obstruction (arrow-
head) was nearly complete (A). After PTBA, the membranous obstruction disappeared
(B), but restenosis (arrow) developed 3 years later (C) and was successfully treated by
repeat PTBA (D). After another 4.25 years, restenosis again developed (E), and the
patient underwent a third PTBA followed by stent placement with a good result (F). The
stent situated between the 8th and 9th thoracic vertebral bodies was better seen on the ﬂat
plate of the abdomen (G).
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progressively inﬂated. Other advantages of the Inoue balloon
catheter include 1) lower inﬂation pressure (1 to 2 atm); 2)
shorter duration of inﬂation (3 s); 3) stronger rubber-nylon
micromeshed balloon than polyethylene balloon; and 4) need
for only one single-balloon catheter with adjustable balloon
sizes depending on the inﬂation volume of the saline-diluted
Renograﬁn-76 mixture used.
PTBA versus stenting. Restenosis after PTBA for MOVC
can be treated either with redilation or with stents. The limited
number worldwide of published cases of stent use in MOVC
(12–18) should make one proceed with caution. Furthermore,
the placement of stents not only adds cost to the procedure but
may interfere with orthotopic liver transplantation, which may
ultimately be indicated in patients with severe ﬁbrosis or
end-stage liver dysfunction (1).
The development of restenosis in only one patient in our
series after PTBA without stent placement is certainly most
encouraging. We therefore believe that most cases of MOVC
can be managed by PTBA without stenting. We propose that
the use of a stent be considered only under the following
circumstances: 1) restenosis after repeat PTBA; 2) long seg-
mental obstruction of the inferior vena cava; or 3) enlarged
caudate lobe of the liver, hepatoma or other abdominal tumor
that may impinge on the inferior vena cava.
Only one patient in our series had restenosis. She was the
ﬁrst patient in our series, and in her procedure we used a
balloon whose diameter was only 18 mm, which was clearly
suboptimal. In subsequent patients we used larger balloon
diameters (20 to 25 mm; average 23 mm). Our ﬁrst patient
underwent repeat PTBA when restenosis developed 3 years
after the initial procedure, and she remained asymptomatic for
another 4.25 years, when restenosis again developed. She
underwent a third PTBA combined with placement of a stent,
and she remained well afterward.
Conclusions. BCS is a rare condition, and treatment guide-
lines have generally been based on anecdotal reports of small
number of patients. However, the recent report (10) that BCS
was present in nearly 10% of patients treated surgically for
portal hypertension indicated that it may be less rare than
previously thought. Despite the wide geographic variability in
the etiology and manifestations of BCS, it has been said (19)
that, Kipling to the contrary, East and West do meet in the
modern management of BCS. Major advances in diagnosis and
treatment of BCS over the past decade plus the encouraging
long-term results of PTBA in our patients with MOVC should
prompt continuation of the recent resurgence of interest in this
condition (7,20–23).
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